siRNA gelsolin knockdown induces epithelial-mesenchymal transition with a cadherin switch in human mammary epithelial cells

International Journal of Cancer

Volumn 118, Issue 7, 2006, Pages 1680-1691

  Tanaka, Hiroki ^a   Shirkoohi, Reza ^a   Nakagawa, Koji ^a   Qiao, Hongjiang ^a   Fujita, Hisakazu ^b   Okada, Futoshi ^c   Hamada, Jun Ichi ^a   Kuzumaki, Satoshi ^a   Takimoto, Masato ^a   Kuzumaki, Noboru ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

^b NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

^c YAMAGATA UNIVERSITY   (Japan)

Author keywords

Actin regulatory protein; EMT; Small interfering RNA

Indexed keywords

ACTIN; GLYCOGEN SYNTHASE KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE; NERVE CELL ADHESION MOLECULE; PROTEIN KINASE B; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR SNAIL; UVOMORULIN;

ACTIN FILAMENT; ARTICLE; BREAST EPITHELIUM; BREAST TUMOR; CARCINOGENESIS; CELL ADHESION; CELL INVASION; CELL LINE; CELL MOTILITY; CELL STRUCTURE; CELL TRANSFORMATION; CONTACT INHIBITION; CONTROLLED STUDY; CULTURE MEDIUM; ENZYME INACTIVATION; EPITHELIUM CELL; FIBROBLAST; HUMAN; HUMAN CELL; MESENCHYME CELL; MONOLAYER CULTURE; PRIORITY JOURNAL; PROTEIN FUNCTION;

BREAST NEOPLASMS; CADHERINS; CELL ADHESION; CELL LINE; CELL MOVEMENT; CELL TRANSFORMATION, NEOPLASTIC; EPITHELIAL CELLS; EPITHELIUM; FEMALE; FIBROBLASTS; GELSOLIN; GENES, SWITCH; GLYCOGEN SYNTHASE KINASE 3; HUMANS; MAMMARY GLANDS, HUMAN; MESODERM; PROTO-ONCOGENE PROTEINS C-AKT; RNA, SMALL INTERFERING; TRANSCRIPTION FACTORS;

EID: 33644863795     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.21559     Document Type: Article

References (65)

1. Yin HL, Stossel TP. Control of cytoplasmic actin gel-sol transformation by gelsolin, a calcium-dependent regulatory protein. Nature 1979; 281:583-6.
2. Sun HQ, Yamamoto M, Mejillano M, Yin HL. Gelsolin, a multifunctional actin regulatory protein. J Biol Chem 1999;274:33179-82.
3. Kwiatkowski DJ. Functions of gelsolin: motility, signaling, apoptosis, cancer. Curr Opin Cell Biol 1999;11:103-8.
4. Chaponnier C, Gabbiani G. Gelsolin modulation in epithelial and stromal cells of mammary carcinoma. Am J Pathol 1989;134:597-603.
5. Winston JS, Asch HL, Zhang PJ, Edge SB, Hyland A, Asch BB. Downregulation of gelsolin correlates with the progression to breast carcinoma. Breast Cancer Res Treat 2001;65:11-21.
6. Moriya S, Yanagihara K, Fujita H, Kuzumaki N. Differential expression of HSP90, gelsolin and GST-π in human gastric carcinoma cell lines. Int J Oncol 1994;5:1347-51.
7. Furuuchi K, Fujita H, Tanaka M, Shichinohe T, Senmaru N, Ogiso Y, Moriya S, Hamada M, Kato H, Kuzumaki N. Gelsolin as a suppressor of malignant phenotype in human colon cancer. Tumor Target 1997; 2:277-83.
8. Tanaka M, Mullauer L, Ogiso Y, Fujita H, Moriya S, Furuuchi K, Harabayashi T, Shinohara N, Koyanagi T, Kuzumaki N. Gelsolin: a candidate for suppressor of human bladder cancer. Cancer Res 1995; 55:3228-32.
9. Dosaka-Akita H, Hommura F, Fujita H, Kinoshita I, Nishi M, Morikawa T, Katoh H, Kawakami Y, Kuzumaki N. Frequent loss of gelsolin expression in non-small cell lung cancers of heavy smokers. Cancer Res 1998;58:322-7.
10. Lee HK, Driscoll D, Asch H, Asch B, Zhang PJ. Downregulated gelsolin expression in hyperplastic and neoplastic lesions of the prostate. Prostate 1999;40:14-19.
11. Visapaa H, Bui M, Huang Y, Seligson D, Tsai H, Pantuck A, Figlin R, Rao JY, Belldegrun A, Horvath S, Palotie A. Correlation of Ki-67 and gelsolin expression to clinical outcome in renal clear cell carcinoma. Urology 2003;61:845-50.
12. Noske A, Denken C, Schober H, Sers C, Zhumabayeva B, Weichen W, Dietel M, Wiechen K. Loss of Gelsolin expression in human ovarian carcinomas. Eur J Cancer 2005;41:461-9.
13. Shieh DB, Godleski J, Herndon JE, II, Azuma T, Mercer H, Sugarbaker DJ, Kwiatkowski DJ. Cell motility as a prognostic factor in stage I nonsmall cell lung carcinoma: the role of gelsolin expression. Cancer 1999;85:47-57.
14. Rao J, Seligson D, Visapaa H, Horvath S, Eeva M, Michel K, Pantuck A, Belldegrun A, Palotie A. Tissue microarray analysis of cytoskeletal actin-associated biomarkers gelsolin and E-cadherin in urothelial carcinoma. Cancer 2002;95:1247-57.
15. Thor AD, Edgerton SM, Liu S, Moore DH, II, Kwiatkowski DJ. Gelsolin as a negative prognostic factor and effector of motility in erbB-2-positive epidermal growth factor receptor-positive breast cancers. Clin Cancer Res 2001;7:2415-24.
16. Cunningham CC, Stossel TP, Kwiatkowski DJ. Enhanced motility in MH 3T3 fibroblasts that overexpress gelsolin. Science 1991;251:1233-6.
17. Arora PD, McCulloch CA. Dependence of fibroblast migration on actin severing activity of gelsolin. J Biol Chem 1996;271:20516-23.
18. De Corte V, Bruyneel E, Boucherie C, Mareel M, Vandekerckhove J, Gettemans J. Gelsolin-induced epithelial cell invasion is dependent on Ras-Rac signaling. EMBO J 2002;21:6781-90.
19. Tanaka M, Sazawa A, Shinohara N, Kobayashi Y, Fujioka Y, Koyanagi T. Kuzumaki N. Gelsolin gene therapy by retrovirus producer cells for human bladder cancer in nude mice. Cancer Gene Ther 1999;6:482-7.
20. Sazawa A, Watanabe T, Tanaka M, Haga K, Fujita H, Harabayashi T, Shinohara N, Koyanagi T, Kuzumaki N. Adenovirus mediated gelsolin gene therapy for orthotopic human bladder cancer in nude mice. J Urol 2002;168:1182-7.
21. Sagawa N, Fujita H, Banno Y, Nozawa Y, Katoh H, Kuzumaki N. Gelsolin suppresses tumorigenicity through inhibiting PKC activation in a human lung cancer cell line, PC10. Br J Cancer 2003;88:606-12.
22. Fujita H, Okada F, Hamada J, Hosokawa M, Moriuchi T, Koya RC, Kuzumaki N. Gelsolin functions as a metastasis suppressor in B16-BL6 mouse melanoma cells and requirement of the carboxyl-terminus for its effect. Int J Cancer 2001;93:773-80.
23. Zhang J, Hua ZC. Targeted gene silencing by small interfering RNA-based knock-down technology. Curr Pharm Biotechnol 2004;5:1-7.
24. Miller FR, Soule HD, Tait L, Pauley RJ, Wolman SR, Dawson PJ, Heppner GH. Xenograft model of progressive human proliferative breast disease. J Natl Cancer Inst 1993;85:1725-32.
25. Kawasaki H, Suyama E, Iyo M. Taira K. siRNAs generated by recombinant human Dicer induce specific and significant but target site-independent gene silencing in human cells. Nucleic Acids Res 2003;31:981-7.
26. Kuzumaki N, Oda A, Yamagiwa S, Taniguchi N, Kobayashi H, Oikawa T. Establishment of four mouse hybridoma cell lines producing monoclonal antibodies reactive with RAS oncogene product p21. J Natl Cancer Inst 1986;77:1273-79.
27. Albrecht-Buehler G. Phagokinetic tracks of 3T3 cells: parallels between the orientation of track segments and of cellular structures which contain actin or tubulin. Cell 1977;12:333-9.
28. Dhawan J, Helfman DM. Modulation of acto-myosin contractility in skeletal muscle myoblasts uncouples growth arrest from differentiation. J Cell Sci 2004;117:3735-48.
29. Miyoshi A, Kitajima Y, Sumi K, Sato K, Hagiwara A, Koga Y, Miyazaki K. Snail and SIPI increase cancer invasion by upregulating MMP family in hepatocellular carcinoma cells. Br J Cancer 2004;90:1265-73.
30. Matsuzaki K, Minami T, Tojo M, Honda Y, Saitoh N, Nagahiro S, Saya H, Nakao M. PML-nuclear bodies are involved in cellular serum response. Gene Cell 2003;8:275-86.
31. Boyer B, Valles AM, Edme N. Induction and regulation of epithelialmesenchymal transitions. Biochem Pharmacol 2000;60:1091-9.
32. Savagner P. Leaving the neighborhood: molecular mechanisms involved during epithelial-mesenchymal transition. Bioessays 2001;23: 912-23.
33. Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2002;2:442-54.
34. Takeichi M. Cadherin cell adhesion receptors as a morphogenetic regulator. Science 1991;251:1451-5.
35. Ciardiello F, Gottardis M, Basolo F, Pepe S, Normanno N, Dickson RB, Bianco AR, Salomon DS. Additive effects of c-erbB-2, c-Ha-ras, and transforming growth factor-α genes on in vitro transformation of human mammary epithelial cells. Mol Carcinog 1992;6:43-52.
36. Zondaga GCM, Eversa EE, ten Kloostera JP, Janssena L, van der Kammena RA, Collarda JG. Oncogenic ras downregulates rac activity, which leads to increased rho activity and epithelial-mesenchymal transition. J Cell Biol 2000;149:775-782.
37. Ward KR, Zhang KX, Somasiri AM, Roskelley CD, Schrader JW. Expression of activated M-Ras in a murine mammary epithelial cell line induces epithelial-mesenchymal transition and tumorigenesis. Oncogene 2004;23:1187-96.
38. Zhou BP, Deng J, Xia W, Xu J, Li YM, Gunduz M, Hung MC. Dual regulation of Snail by GSK3-mediated phosphorylation in control of epithelial-mesenchymal transition. Nat Cell Biol 2004;6:931-40.
39. Bachelder RE, Yoon SO, Franci C, de Herreros AG, Mercurio AM. Glycogen synthase kinase-3 is an endogenous inhibitor of Snail transcription: implications for the epithelial-mesenchymal transition. J Cell Biol 2005;168:29-33.
40. Batlle E, Sancho E, Franci C, Dominguez D, Monfar M, Baulida J, Garcia De Herreros A. The transcription factor snail is a repressor of E-cadherin gene expression in epithelial tumour cells. Nat Cell Biol 2000;2:84-9.
41. Elenbaas B, Spirio L, Koerner F, Fleming MD, Zimonjic DB, Donaher JL, Popescu NC, Hahn WC, Weinberg RA. Human breast cancer cells generated by oncogenic transformation of primary mammary epithelial cells. Genes Dev 2001;15:50-65.
42. Crowley MR, Head KL, Kwiatkowski DJ, Asch HL, Asch BB. The mouse mammary gland requires the actin-binding protein gelsolin for proper ductal morphogenesis. Dev Biol 2000;225:407-23.
43. Gilles C, Thompson EW. The epithelial to mesenchymal transition and metastatic progression in carcinoma. Breast J 1996;2:83-6.
44. Petersen OW, Nielsen HL, Gudjonsson T, Villadsen R, Rank F, Niebuhr E, Bissell MJ, Ronnov-Jessen L. Epithelial to mesenchymal transition in human breast cancer can provide a nonmalignant stroma. Am J Pathol 2003;162:391-402.
45. Avizienyte E, Fincham VJ, Brunton VG, Frame MC. Src SH3/2 domain-mediated peripheral accumulation of Src and phospho-myosin is linked to deregulation of E-cadherin and the epithelial-mesenchymal transition. Mol Biol Cell 2004;15:2794-803.
46. Grille SJ, Bellacosa A, Upson J, Klein-Szanto AJ, van Roy F, Lee-Kwon W, Donowitz M, Tsichlis PN, Lame L. The protein kinase AKT induces epithelial mesenchymal transition and promotes enhanced motility and invasiveness of squamous cell carcinoma lines. Cancer Res 2003;63:2172-8.
47. Ellenrieder V, Hendler SF, Boeck W, Seufferlein T, Menke A, Ruhland C, Adler G, Gress TM. Transforming growth factor β1 treatment leads to an epithelial-mesenchymal transdifferentiation of pancreatic cancer cells requiring extracellular signal-regulated kinase 2 activation. Cancer Res 2001;61:4222-8.
48. Bakin AV, Tomlinson AK, Bhowmick NA, Moses HL, Arteaga CL. Phosphatidylinositol 3-kinase function is required for transforming growth factor β-mediated epithelial to mesenchymal transition and cell migration. J Biol Chem 2000;275:36803-10.
49. Small JV. Lamellipodia architecture: actin filament turnover and the lateral flow of actin filaments during motility. Semin Cell Biol 1994; 5:157-63.
50. Hilpela P, Vartiainen MK, Lappalainen P. Regulation of the actin cytoskeleton by PI(4,5)P2 and PI(3,4,5)P3. Curr Top Microbiol Immunol 2004;282:117-63.
51. Azuma T, Witke W, Stossel TP, Hartwig JH, Kwiatkowski DJ. Gelsolin is a downstream effector of rac for fibroblast motility. EMBO J 1998;17:1362-70.
52. Keely PJ, Westwick JK, Whitehead IP, Der CJ, Parise LV. Cdc42 and Rac1 induce integrin-mediated cell motility and invasiveness through PI(3)K. Nature 1997;390:632-6.
53. Nosaka Y, Arai A, Kanda E, Akasaki T, Sumimoto H, Miyasaka N, Miura O. Rac is activated by tumor necrosis factor a and is involved in activation of Erk, Biochem Biophy Res Commun 2001;285:675-9.
54. Eldar-Finkelman H, Seger R, Vandenheede JR, Krebs EG. Inactivation of glycogen synthase kinase-3 by epidermal growth factor is mediated by mitogen-activated protein kinase/p90 ribosomal protein S6 kinase signaling pathway in NIH/3T3 cells. J Biol Chem 1995; 270:987-90.
55. Salas TR, Reddy SA, Clifford JL, Davis RJ, Kikuchi A, Lippman SM, Menter DG. Alleviating the suppression of glycogen synthase kinase-3 3β by AKT leads to the phosphorylation of cAMP-response element-binding protein and its transactivation in intact cell nuclei. J Biol Chem 2003;278:41338-46.
56. Hazan RB, Qiao R, Keren R, Badano I, Suyama K. Cadherin switch in tumor progression. Ann N Y Acad Sci 2004;1014:155-63.
57. Van Aken E, De Wever O, Correia da Rocha AS, Mareel M. Defective E-cadherin/catenin complexes in human cancer. Virchows Arch 2001;439:725-51.
58. Cavallaro U, Christofori G. Cell adhesion and signalling by cadherins and Ig-CAMs in cancer. Nat Rev Cancer 2004;4:118-32.
59. Kim JB, Islam S, Kim YJ, Prudoff RS, Sass KM, Wheelock MJ, Johnson KR. N-Cadherin extracellular repeat 4 mediates epithelial to mesenchymal transition and increased motility. J Cell Biol 2000;151: 1193-206.
60. Chan MW, El Sayegh TY, Arora PD, Laschinger CA, Overall CM, Morrison C, McCulloch CA. Regulation of intercellular adhesion strength in fibroblasts. J Biol Chem 2004;279:41047-57.
61. Machesky LM, Insall RH. Signaling to actin dynamics. J Cell Biol 1999;146:267-72.
62. Braga VM, Betson M, Li X, Lamarche-Vane N. Activation of the small GTPase ORac is sufficient to disrupt cadherin-dependent cell-cell adhesion in normal human keratinocytes. Mol Biol Cell 2000;11: 3703-21.
63. Lozano E, Betson M, Braga VM. Tumor progression: small GTPases and loss of cell-cell adhesion. Bioessays 2003;25;452-63.
64. Liu J, Stevens J, Rote CA, Yost HJ, Hu Y, Neufeld KL, White RL, Matsunami N. Siah-1 mediates a novel β-catenin degradation pathway linking p53 to the adenomatous polyposis coli protein. Mol Cell 2001;7:927-36.
65. Nieto MA. The snail superfamily of zinc-finger transcription factors. Nat Rev Mol Cell Biol 2002;3:155-66.